172 related articles for article (PubMed ID: 17608406)
41. Identification of novel HIV-1 integrase inhibitors using shape-based screening, QSAR, and docking approach.
Gupta P; Garg P; Roy N
Chem Biol Drug Des; 2012 May; 79(5):835-49. PubMed ID: 22233531
[TBL] [Abstract][Full Text] [Related]
42. X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors.
Majerz-Maniecka K; Musiol R; Skórska-Stania A; Tabak D; Mazur P; Oleksyn BJ; Polanski J
Bioorg Med Chem; 2011 Mar; 19(5):1606-12. PubMed ID: 21316973
[TBL] [Abstract][Full Text] [Related]
43. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors.
Mustata GI; Brigo A; Briggs JM
Bioorg Med Chem Lett; 2004 Mar; 14(6):1447-54. PubMed ID: 15006380
[TBL] [Abstract][Full Text] [Related]
44. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
45. Synthesis of novel thiazolothiazepine based HIV-1 integrase inhibitors.
Aiello F; Brizzi A; Garofalo A; Grande F; Ragno G; Dayam R; Neamati N
Bioorg Med Chem; 2004 Aug; 12(16):4459-66. PubMed ID: 15265496
[TBL] [Abstract][Full Text] [Related]
46. Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
Rajamaki S; Innitzer A; Falciani C; Tintori C; Christ F; Witvrouw M; Debyser Z; Massa S; Botta M
Bioorg Med Chem Lett; 2009 Jul; 19(13):3615-8. PubMed ID: 19447621
[TBL] [Abstract][Full Text] [Related]
47. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75.
Du L; Zhao Y; Chen J; Yang L; Zheng Y; Tang Y; Shen X; Jiang H
Biochem Biophys Res Commun; 2008 Oct; 375(1):139-44. PubMed ID: 18691555
[TBL] [Abstract][Full Text] [Related]
48. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors.
Deng J; Lee KW; Sanchez T; Cui M; Neamati N; Briggs JM
J Med Chem; 2005 Mar; 48(5):1496-505. PubMed ID: 15743192
[TBL] [Abstract][Full Text] [Related]
49. New approaches for inhibiting HIV integrase: a journey beyond the active site.
Walker MA
Curr Opin Investig Drugs; 2009 Feb; 10(2):129-36. PubMed ID: 19197790
[TBL] [Abstract][Full Text] [Related]
50. Design and synthesis of photoactivatable aryl diketo acid-containing HIV-1 integrase inhibitors as potential affinity probes.
Zhang X; Marchand C; Pommier Y; Burke TR
Bioorg Med Chem Lett; 2004 Mar; 14(5):1205-7. PubMed ID: 14980666
[TBL] [Abstract][Full Text] [Related]
51. Amide-containing diketoacids as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity.
Li H; Wang C; Sanchez T; Tan Y; Jiang C; Neamati N; Zhao G
Bioorg Med Chem; 2009 Apr; 17(7):2913-9. PubMed ID: 19269185
[TBL] [Abstract][Full Text] [Related]
52. A quantum mechanics/molecular mechanics study of the protein-ligand interaction for inhibitors of HIV-1 integrase.
Alves CN; Martí S; Castillo R; Andrés J; Moliner V; Tuñón I; Silla E
Chemistry; 2007; 13(27):7715-24. PubMed ID: 17570717
[TBL] [Abstract][Full Text] [Related]
53. Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase.
Barreca ML; De Luca L; Iraci N; Chimirri A
J Med Chem; 2006 Jun; 49(13):3994-7. PubMed ID: 16789757
[TBL] [Abstract][Full Text] [Related]
54. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
55. HIV-1 integrase complexes with DNA dissociate in the presence of short oligonucleotides conjugated to acridine.
Pinskaya M; Romanova E; Volkov E; Deprez E; Leh H; Brochon JC; Mouscadet JF; Gottikh M
Biochemistry; 2004 Jul; 43(27):8735-43. PubMed ID: 15236582
[TBL] [Abstract][Full Text] [Related]
56. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
[TBL] [Abstract][Full Text] [Related]
57. Modeling HIV-1 integrase complexes based on their hydrodynamic properties.
Podtelezhnikov AA; Gao K; Bushman FD; McCammon JA
Biopolymers; 2003 Jan; 68(1):110-20. PubMed ID: 12579583
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, molecular modeling, and anti-HIV-1 integrase activity of a series of photoactivatable diketo acid-containing inhibitors as affinity probes.
Sechi M; Carta F; Sannia L; Dallocchio R; Dessì A; Al-Safi RI; Neamati N
Antiviral Res; 2009 Mar; 81(3):267-76. PubMed ID: 19135482
[TBL] [Abstract][Full Text] [Related]
59. HIV-1 integrase inhibitors: 2003-2004 update.
Dayam R; Deng J; Neamati N
Med Res Rev; 2006 May; 26(3):271-309. PubMed ID: 16496343
[TBL] [Abstract][Full Text] [Related]
60. Development of a receptor model for efficient in silico screening of HIV-1 integrase inhibitors.
Quevedo MA; Ribone SR; Briñón MC; Dehaen W
J Mol Graph Model; 2014 Jul; 52():82-90. PubMed ID: 25023663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
